DA Den Europæiske Unions Tidende C 44/6

Medicinske specialiteter — Liste over markedsføringstilladelser udstedt af EØS-EFTA-staterne i første halvdel af 2011

2012/C 44/05

Underudvalg I for frie varebevægelser

Til Det Blandede EØS-udvalgs underretning

Under henvisning til afgørelse truffet af Det Blandede EØS-udvalg nr. 74/1999 af 28. maj 1999 opfordres Det Blandede EØS-udvalg til på sit møde den 30. september 2011 at notere sig følgende lister over markedsføringstilladelser for medicinske specialiteter udstedt i perioden 1. januar-30. juni 2011:

Bilag I Liste over nye markedsføringstilladelser Bilag II Liste over fornyede markedsføringstilladelser Bilag III Liste over udvidede markedsføringstilladelser Bilag IV Liste over tilbagetrukne markedsføringstilladelser Bilag V Liste over suspenderede markedsføringstilladelser

BILAG I Liste over nye markedsføringstilladelser Følgende markedsføringstilladelser er blevet udstedt i EØS-EFTA-staterne i perioden 1. januar-30. juni 2011: EU-Nummer Produkt Land Udstedelsesdato EU/1/09/578/001 Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals Island 29.4.2011 EU/1/10/635/001-014 Olanzapin Apotex Norge 14.2.2011 EU/1/10/639/001-030 Telmisartan Actavis Norge 17.3.2011 EU/1/10/641/001 Ruconest Island 24.1.2011 EU/1/10/642/001-004 Ibandronic Acid Roche Island 17.1.2011 EU/1/10/647/001-002 Myclausen Island 21.1.2011 EU/1/10/647/001-028 Twynsta Island 21.1.2011 EU/1/10/650/001-015 Clopidogrel Teva Generics B.V. Island 1.2.2011 EU/1/10/651/001-015 Clopidogrel HCS Island 1.2.2011 EU/1/10/654/001-004 Leflunomide ratiopharm Island 14.3.2011 EU/1/10/656/001-006 Possia Island 13.1.2011 EU/1/10/656/001-006 Possia Norge 25.1.2011 EU/1/10/657/001-002 Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Dia Island 14.3.2011 EU/1/10/657/001-002 Prepandemic influenza vaccine Norge 3.1.2011 EU/1/10/658/001-002 Aflunov Island 14.3.2011 EU/1/10/658/001-002 Aflunov Norge 3.1.2011 EU/1/10/659/001-010 Iasibon Island 14.2.2011 EU/1/10/659/001-010 Iasibon Norge 17.2.2011 EU/1/10/659/001-010 Iasibon Liechtenstein 28.2.2011 EU/1/10/660/001-002 Potactasol Island 16.3.2011 EU/1/10/660/001-002 Potactasol Liechtenstein 28.2.2011 EU/1/10/661/001-002 Fluenz Island 16.3.2011 EU/1/10/661/001-002 Fluenz Liechtenstein 28.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Island 17.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Liechtenstein 28.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Norge 17.3.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Norge 17.3.2011 EU/1/10/663/001-002 Lamivudine/Zidovudine Teva Norge 31.3.2011 EU/1/10/663/001-002 Lamivudine/Zidovudine Teva Liechtenstein 30.4.2011 EU/1/10/664/001 Pumarix Island 8.4.2011 EU/1/10/664/001 Pumarix Norge 13.4.2011 EU/1/10/664/001 Pumarix Liechtenstein 30.4.2011 EU/1/10/665/001-004 Entacapone Teva Island 21.3.2011 EU/1/10/665/001-004 Entacapone Teva Norge 4.4.2011 EU/1/10/665/001-004 Entacapone Teva Liechtenstein 30.4.2011 EU/1/11/666/001-003 Libertek Island 24.3.2011 EU/1/11/666/001-003 Libertek Norge 15.3.2011 EU/1/11/666/001-003 Libertek Liechtenstein 30.4.2011 EU/1/11/667/001-003 Esbriet Liechtenstein 30.4.2011 EU/1/11/667/001-003 Esbriet Island 25.3.2011 EU/1/11/667/001-003 Esbriet Norge 15.3.2011 EU/1/11/667/001-003 Esbriet Norge 15.3.2011 EU/1/11/668/001-003 Daliresp Island 12.4.2011 EU/1/11/668/001-003 Daliresp Norge 15.3.2011 EU/1/11/668/001-003 Daliresp Liechtenstein 30.4.2011 EU/1/11/669/001-004 Teysuno Island 12.4.2011 EU/1/11/669/001-004 Teysuno Norge 24.5.2011 EU/1/11/669/001-004 Teysuno Liechtenstein 30.4.2011 EU/1/11/671/001 Xiapex Island 28.3.2011 EU/1/11/671/001 Xiapex Norge 31.3.2011 EU/1/11/671/001 Xiapex Liechtenstein 30.4.2011 EU/1/11/672/001-006 Xeplion Island 8.4.2011 EU/1/11/672/001-006 Xeplion Norge 5.4.2011 EU/1/11/672/001-006 Xeplion Liechtenstein 30.4.2011 EU/1/11/673/001-024 Ifirmacombi Island 4.4.2011 EU/1/11/673/001-024 Ifirmacombi Norge 6.4.2011 EU/1/11/673/001-024 Ifirmacombi Liechtenstein 30.4.2011 EU/1/11/674/001-010 Repso Island 13.4.2011 EU/1/11/674/001-010 Repso Norge 26.4.2011 EU/1/11/674/001-010 Repso Liechtenstein 30.4.2011 EU/1/11/675/001-0010 Leflunomide Teva Island 8.4.2011 EU/1/11/675/001-010 Lefluomide Teva Norge 11.4.2011 EU/1/11/675/001-010 Leflunomid Teva Liechtenstein 30.4.2011 EU/1/11/676/001 Jevtana Island 12.4.2011 EU/1/11/676/001 Jevtana Norge 6.4.2011 EU/1/11/676/001 Jevtana Liechtenstein 30.4.2011 EU/1/11/677/001-004 Gilenya Island 13.4.2011 EU/1/11/677/001-004 Gilenya Norge 28.3.2011 EU/1/11/677/001-004 Gilenya Liechtenstein 30.4.2011 EU/1/11/678/001-002 Halaven Island 14.4.2011 EU/1/11/678/001-002 Halaven Norge 6.4.2011 EU/1/11/678/001-002 Halaven Liechtenstein 30.4.2011 EU/1/11/679/001-006 Pravafenix Island 10.5.2011 EU/1/11/679/001-006 Pravafenix Norge 11.5.2011 EU/1/11/679/001-006 Pravafenix Liechtenstein 30.4.2011 EU/1/11/680/001-080 Riprazo HCT Island 29.4.2011 EU/1/11/680/001-080 Riprazo HCT Norge 24.5.2011 EU/1/11/680/001-080 Riprazo HCT Liechtenstein 30.4.2011 EU/1/11/681/001-013 Trobalt Island 19.4.2011 EU/1/11/681/001-013 Trobalt Norge 4.4.2011 EU/1/11/681/001-013 Trobalt Liechtenstein 30.6.2011 EU/1/11/681/001-013 Trobalt Liechtenstein 30.4.2011 EU/1/11/682/001 Methylthioninium chloride Proveblue Island 6.6.2011 EU/1/11/682/001 Methylhionininium chloride Proveblue Norge 27.6.2011 EU/1/11/682/001 Methylthioninchlorid Proveblue Liechtenstein 30.6.2011 EU/1/11/686/001-056 Rasilamlo Island 12.5.2011 EU/1/11/686/001-056 Rasilamlo Norge 24.5.2011 EU/1/11/686/001-056 Rasilamlo Liechtenstein 30.4.2011 EU/1/11/687/001-012 Hizentra Island 12.5.2011 EU/1/11/687/001-012 Hizentra Norge 9.5.2011 EU/1/11/687/001-012 Hizentra Liechtenstein 30.4.2011 EU/1/11/688/001 Cinryze Island 28.6.2011 EU/1/11/688/001 Cinryze Norge 27.6.2011 EU/1/11/691/001-005 Eliquis Norge 31.5.2011 EU/1/11/691/001-005 Eliquis Liechtenstein 30.6.2011 EU/1/11/692/001 Yellox Island 28.6.2011 EU/1/11/692/001 Yellox Norge 10.6.2011 EU/1/11/692/001 Yellox Liechtenstein 30.6.2011 EU/1/11/693/001-016 Rivastigmine Actavis Island 28.6.2011 EU/1/11/693/001-016 Rivastigmine Actavis Liechtenstein 30.6.2011 EU/1/190/649/001-016 Clopidogrel Teva Pharma B.V. Island 30.6.2011 EU/1/98/058/001-002 Lamivudine/Zidovudine Teva Island 12.4.2011 EU/1/98/058/001-002 Lamivudine Norge 31.3.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Liechtenstein 30.4.2011 EU/2/11/126/001 MS-H Impfstoff Liechtenstein 30.6.2011 EU/2/10/107/001-014 Veraflox Island 10.5.2011 EU/2/10/107/001-014 Veraflox Norge 24.6.2011 EU/2/10/107/001-014 Veraflox Liechtenstein 30.4.2011 EU/2/10/109/001-009 RHINISENG Norge 3.1.2011 EU/2/10/110/001-002 Coxevac Island 26.1.2011 EU/2/10/111/001-004 Meloxoral Island 14.3.2011 EU/2/10/111/001-004 Meloxoral Norge 3.1.2011 EU/2/10/112/001-005 BTVPUR ALSap 1 Island 10.2.2011 EU/2/10/112/001-005 BTVPUR ALSap 1 Liechtenstein 28.2.2011 EU/2/10/113/001-005 BTVPUR ALSap 1-8 Island 10.2.2011 EU/2/10/113/001-005 BTVPU ALSap 1-8 Liechtenstein 28.2.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Island 16.3.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Norge 9.2.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Liechtenstein 28.2.2011 EU/2/10/115/001-010 Comfortis Island 22.3.2011 EU/2/10/115/001-010 Comfortis Norge 22.2.2011 EU/2/10/115/001-010 Comfortis Liechtenstein 30.4.2011 EU/2/10/115/001-010 Comfortis Norge 22.2.2011 EU/2/10/116/001-004 Melosus Island 24.3.2011 EU/2/10/116/001-004 Melosus Norge 14.4.2011 EU/2/10/116/001-004 Melosus Liechtenstein 30.4.2011 EU/2/10/117/001-002 Purevax Rabies Island 21.3.2011 EU/2/10/117/001-002 Purevax Rabies Norge 4.4.2011 EU/2/10/117/001-002 Purevax Rabies Liechtenstein 30.4.2011 EU/2/10/118/001-014 Activyl Island 21.3.2011 EU/2/10/118/001-014 Activyl Norge 1.4.2011 EU/2/10/118/001-014 Activyl Liechtenstein 30.4.2011 EU/2/10/119/001-012 Cimalgex Island 21.3.2011 EU/2/10/119/001-012 Cimalgex Norge 1.4.2011 EU/2/108/001-005 BTVPUR ALSap 2-4 0.72 U.SN Island 10.2.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Island 13.4.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Norge 18.4.2011 EU/2/11/121/001-009 CaniLeish Island 13.4.2011 EU/2/11/121/001-009 CaniLeish Norge 11.4.2011 EU/2/11/121/001-009 CaniLeish Liechtenstein 30.4.2011 EU/2/11/123/001-002 Procox Island 28.6.2011 EU/2/11/123/001-002 Procox Norge 20.6.2011 EU/2/11/123/001-002 Procox Liechtenstein 30.6.2011 EU/2/11/124/001-008 Zuprevo Island 6.6.2011 EU/2/11/124/001-008 Zuprevo Liechtenstein 30.6.2011 EU/2/11/125/001-008 Certifect Island 6.6.2011 EU/2/11/125/001-008 Certificet Liechtenstein 30.6.2011 EU/2/11/126/001 MS-H-vaccine Island 28.6.2011

BILAG II Liste over fornyede markedsføringstilladelser Følgende markedsføringstilladelser er blevet fornyet i EØS-EFTA-staterne i perioden 1. januar-30. juni 2011: EU-Nummer Produkt Land Udstedelsesdato EU/1/00/135/001-002 DaTSCAN Island 14.3.2011 EU/1/00/149/001 Panretin Island 18.1.2011 EU/1/00/156/002-004 Trizivir Island 14.2.2011 EU/1/00/166/001-003 NeuroBloc Island 15.2.2011 EU/1/00/166/001-003 NeuroBloc Norge 15.2.2011 EU/1/00/167/001-008 Prevenar Island 25.3.2011 EU/1/00/167/001-008 Prevenar Norge 3.3.2011 EU/1/00/167/001-008 Prevenar Liechtenstein 28.2.2011 EU/1/00/173/001-003 Vaniqa Island 15.4.2011 EU/1/01/171/001, 007-010, 013-014 Rapamune Island 21.2.2011 EU/1/01/171/001, EU/1/01/171/007-010 EU/1/01/171/013-014 Rapamune Norge 2.2.2011 EU/1/01/172/001-008 Kaletra Island 21.3.2011 EU/1/01/172/001-008 Kaletra Norge 27.4.2011 EU/1/01/172/001-008 Kaletra Liechtenstein 30.4.2011 EU/1/01/173/001-003 Vaniqa Norge 3.5.2011 EU/1/01/173/001-003 Vaniqa Liechtenstein 30.4.2011 EU/1/01/179/001 Osigraft Island 17.5.2011 EU/1/01/179/001 Osigraft Norge 15.6.2011 EU/1/01/179/001 Osigraft Liechtenstein 30.6.2011 EU/1/01/183/001&004-005,007-008,011,013,015,018-032 HBVAXPRO Island 18.4.2011 EU/1/01/183/001, EU/1/01/183/004-005 EU/1/01/183/007-008, EU/1/01/183/011 EU/1/01/183/013, EU/1/01/183/015 EU/1/01/183/018-032 HBVAXPRO Norge 14.4.2011 EU/1/01/187/001 DepoCyte Island 23.6.2011 EU/1/01/187/001 DepoCyte Liechtenstein 30.6.2011 EU/1/01/191/001-005 Ketek 400 mg Island 9.6.2011 EU/1/01/191/001-005 Ketek Norge 31.5.2011 EU/1/01/191/001-005 Ketek Liechtenstein 30.6.2011 EU/1/01/193/001-002 MabCampath Island 23.6.2011 EU/1/01/193/001-002 MabCampath Norge 15.6.2011 EU/1/05/312/001 Xyrem Island 14.1.2011 EU/1/05/313/001-009 Ablavar Island 28.1.2011 EU/1/05/314/001 Kepivance Island 17.1.2011 EU/1/05/315/001-002 Aptivus Island 27.1.2011 EU/1/05/320/001 Noxafil Island 18.1.2011 EU/1/05/322/001 Yttriga Island 18.3.2011 EU/1/05/322/001 Yttriga Norge 20.1.2011 EU/1/05/322/001 Yttriga Liechtenstein 28.2.2011 EU/1/05/323/001-013 ProQuad Island 15.4.2011 EU/1/05/323/001-013 ProQuad Norge 6.4.2011 EU/1/05/323/001-013 ProQuad Liechtenstein 30.4.2011 EU/1/05/324/001-002 Naglazyme Island 23.3.2011 EU/1/05/324/001-002 Naglazyme Norge 7.2.2011 EU/1/05/324/001-002 Naglazyme Liechtenstein 28.2.2011 EU/1/05/325/002 Macugen Island 15.2.2011 EU/1/05/325/002 Macugen Norge 1.2.2011 EU/1/05/325/002 Macugen Liechtenstein 28.2.2011 EU/1/05/328/001-004 Cubicin Island 14.2.2011 EU/1/05/328/001-004 Cubicin Norge 11.1.2011 EU/1/05/329/001-006 Kiovig Island 24.2.2011 EU/1/05/329/001-006 Kiovig Norge 2.2.2011 EU/1/05/329/001-006 Kiovig Liechtenstein 28.2.2011 EU/1/05/330/001-011 Rotarix Island 22.3.2011 EU/1/05/330/001-011 Rotarix Norge 13.5.2011 EU/1/05/331/001-055 Neupro Island 15.2.2011 EU/1/05/331/001-055 Neupro Norge 10.1.2011 EU/1/06/332/001-009 Omnitrope Island 28.6.2011 EU/1/06/332/001-009 Omnitrope Norge 5.4.2011 EU/1/06/332/001-009 Omnitrope Liechtenstein 30.4.2011 EU/1/06/333/001-003 Myozyme Island 20.4.2011 EU/1/06/333/001-003 Myozyme Norge 22.3.2011 EU/1/06/333/001-003 Myozyme Liechtenstein 30.4.2011 EU/1/06/334/001-005 Evoltra Island 18.4.2011 EU/1/06/334/001-005 Evoltra Norge 25.5.2011 EU/1/06/334/001-005 Evoltra Liechtenstein 30.4.2011 EU/1/06/335/001 Valtropin Island 12.5.2011 EU/1/06/335/001 Valtropin Norge 3.6.2011 EU/1/06/335/001 Valtropin Liechtenstein 30.4.2011 EU/1/06/336/001 Tygacil Norge 31.5.2011 EU/1/06/336/001 Tygacil Liechtenstein 30.6.2011 EU/1/06/337/001-013 M-M-RVAXPRO Island 16.5.2011 EU/1/06/337/001-013 M-M-RVAXPRO Norge 31.5.2011 EU/1/06/337/001-013 M-M-RVAXPRO Liechtenstein 30.6.2011 EU/1/06/338/001-003 DuoTrav Island 21.1.2011 EU/1/06/339/001-002 Preotact Island 11.5.2011 EU/1/06/339/001-002 Preotact Liechtenstein 30.4.2011 EU/1/06/341/001-013 Zostavax Island 18.4.2011 EU/1/06/341/001-013 Zostavax Liechtenstein 30.4.2011 EU/1/06/343/001-007 Baraclude Island 23.6.2011 EU/1/06/343/001-007 Baraclude Liechtenstein 30.6.2011 EU/1/06/346/001 Tysabri Island 27.6.2011 EU/1/06/348/001-002 RotaTeq Island 23.6.2011 EU/1/06/348/001-002 RotaTeq Norge 17.6.2011 EU/1/06/348/001-002 RotaTeq Liechtenstein 28.2.2011 EU/1/06/354/001-011 Competact Island 24.6.2011 EU/1/06/354/001-011 Competact Norge 23.6.2011 EU/1/06/354/001-011 Competact Liechtenstein 30.6.2011 EU/1/06/360/001-013 Champix Liechtenstein 30.6.2011 EU/1/06/367/001-012 Diacomit Island 11.2.2011 EU/1/06/367/001-012 Diacomit Norge 15.2.2011 EU/1/06/367/001-012 Diacomit Liechtenstein 28.2.2011 EU/1/07/423/001-003 Vectibix Island 15.2.2011 EU/1/07/423/001-003 Vectibix Norge 25.1.2011 EU/1/07/440/001-003 Tyverb Norge 3.6.2011 EU/1/10/625/001 Arzerra Island 22.2.2011 EU/1/10/625/001-002 Arzerra Norge 17.2.2011 EU/1/10/625/001-002 Arzerra Liechtenstein 28.2.2011 EU/1/10/628/001-004 Votrient Island 6.6.2011 EU/1/183/001, 004-005, 007-008, 011, 013, 015, 018-032 HBVAXPRO Liechtenstein 30.4.2011 EU/1/96/009/001-008 Zerit Island 16.5.2011 EU/1/96/009/001-009 Zerit Norge 6.5.2011 EU/1/96/009/001-009 Zerit Liechtenstein 30.4.2011 EU/2/00/026/001-004 Porcilis AR-T DF Norge 3.1.2011 EU/2/00/026/001-006 Porcilis AR-T DF Island 17.1.2011 EU/2/04/045/001-007 Previcox Norge 18.4.2011 EU/2/04/048/001-002 Purevax RCP FeLV Norge 13.4.2011 EU/2/04/049/001-002 Purevax RCCh Norge 13.4.2011 EU/2/04/050/001-002 Purevax RCPCh Norge 13.4.2011 EU/2/04/051/001-002 Purevax RC Norge 13.4.2011 EU/2/04/052/001-002 Purevax RCP Norge 13.4.2011 EU/2/06/058/004 Flexicam Island 8.4.2011 EU/2/06/058/004 Flexicam Norge 26.4.2011 EU/2/06/058/004 Flexicam Liechtenstein 30.4.2011 EU/2/06/059/001 Convenia Island 27.6.2011

BILAG III Liste over udvidede markedsføringstilladelser Følgende markedsføringstilladelser er blevet udvidet i EØS-EFTA-staterne i perioden 1. januar-30. juni 2011: EU-Nummer Produkt Land Udstedelsesdato EU/1/01/185/100-111 Aranesp Island 15.4.2011 EU/1/01/194/003-004 INOmax Island 15.4.2011 EU/1/02/227/003 Neulasta Liechtenstein 30.4.2011 EU/1/06/332/010-012 Omnitrope Island 16.6.2011 EU/1/06/332/010-012 Omnitrope Liechtenstein 30.6.2011 EU/1/06/354/010-011 Competact Liechtenstein 28.2.2011 EU/1/06/354/012 Competact Liechtenstein 30.6.2011 EU/1/06/370/037-039 Exforge Liechtenstein 28.2.2011 EU/1/06/371/037-039 Dafiro Liechtenstein 28.2.2011 EU/1/06/373/037-039 Imprida Liechtenstein 28.2.2011 EU/1/07/387/014-026 Advagraf Liechtenstein 30.6.2011 EU/1/07/397/002-004 Siklos Island 25.3.2011 EU/1/07/397/002-004 Siklos Norge 5.4.2011 EU/1/07/397/002-004 Siklos Liechtenstein 30.4.2011 EU/1/07/401/012-015 Alli Island 16.2.2011 EU/1/07/401/012-015 Alli Norge 26.1.2011 EU/1/07/404/006-008 Flebogamma DIF Island 17.2.2011 EU/1/07/404/006-008 Flebogamma DIF Norge 14.1.2011 EU/1/07/404/006-008 Flebogamma DIF Liechtenstein 28.2.2011 EU/1/07/407/021-040 Sprimeo Liechtenstein 30.4.2011 EU/1/07/410/027-052 Binocrit Liechtenstein 30.4.2011 EU/1/07/411/027-052 Epoetin alfa Hexal Liechtenstein 30.4.2011 EU/1/07/420/002 Cyanokit Island 20.1.2011 EU/1/07/420/002 Cyanokit Norge 14.2.2011 EU/1/07/422/005-006 Tasigna Island 23.3.2011 EU/1/07/422/005-006 Tasigna Norge 21.1.2011 EU/1/07/422/005-006 Tasigna Liechtenstein 28.2.2011 EU/1/07/438/005-006 Myfenax Liechtenstein 30.6.2011 EU/1/07/439/005-006 Mycophenole mofetil Teva Liechtenstein 30.6.2011 EU/1/08/461/002 Firazyr Liechtenstein 30.4.2011 EU/1/08/490/017-024 Pramipexole Teva Liechtenstein 30.6.2011 EU/1/09/511/005 Conbriza Liechtenstein 30.4.2011 EU/1/09/535/015-016 Grepid Liechtenstein 28.2.2011 EU/1/09/545/011-015 Onglyza Island 14.4.2011 EU/1/09/545/011-015 Onglyza Norge 25.3.2011 EU/1/09/545/011-015 Onglyza Liechtenstein 30.4.2011 EU/1/09/581/003-008 Resolor Liechtenstein 28.2.2011 EU/1/10/614/002 Menveo Liechtenstein 30.4.2011 EU/1/96/022/035-040 Zyprexa Liechtenstein 28.2.2011 EU/1/97/033/005-006 Avonex Liechtenstein 30.6.2011 EU/1/99/103/005 ReFacto AF Island 6.6.2011 EU/1/99/103/005-008 ReFacto AF Norge 1.6.2011 EU/1/99/103/005-008 ReFacto AF Liechtenstein 30.6.2011 EU/2/07/078/009-010 Rheumocam Island 18.4.2011 EU/2/07/078/009-010 Rheumocam Norge 9.2.2011 EU/2/07/078/009-010 Rheumocam Liechtenstein 28.2.2011 EU/2/07/078/011-014 Rheumocam Island 28.6.2011 EU/2/07/078/011-014 Rheumocam Liechtenstein 30.6.2011 EU/2/08/082/007 Zactran Liechtenstein 30.6.2011 EU/2/97/004/041-048 Metacam Liechtenstein 28.2.2011 EU/2/98/010/025 Econor Island 18.2.2011 EU/2/98/010/025 Econor Liechtenstein 28.2.2011 EU/99/119/017-018 NovoRapid Liechtenstein 30.4.2011

BILAG IV Liste over tilbagetrukne markedsføringstilladelser Følgende markedsføringstilladelser er blevet trukket tilbage i EØS-EFTA-staterne i perioden 1. januar-30. juni 2011: EU-Nummer Produkt Land Udstedelsesdato EU/1/03/259/001-006 Onsenal Island 20.4.2011 EU/1/03/259/001-006 Onsenal Liechtenstein 30.4.2011 EU/1/05/326/001 Ionsys Island 20.4.2011 EU/1/06/353/001-005 Thelin Island 15.3.2011 EU/1/06/353/001-005 Thelin Liechtenstein 28.2.2011 EU/1/08/449/001-008 Filgrastim ratiopharm Liechtenstein 30.4.2011 EU/1/08/449/001-008 Filgrastim ratiopharm Island 12.5.2011 EU/1/09/542/001-007 Clopidogrel 1A Pharma Liechtenstein 28.2.2011 EU/1/09/542/001-007 Clopidogrel 1A Pharma Island 16.3.2011 EU/1/09/547/001-007 Clopidogrel Sandoz Liechtenstein 30.4.2011 EU/1/10/629/001 Humenza Island 29.6.2011 EU/1/10/629/001 Humenza Liechtenstein 30.6.2011